Blood Cancers: Myeloma, Leukemia and Lymphoma
Personalized Care Options
The UC Cancer Institute Hematologic Malignancies Program offers a unique treatment strategy not available at medical centers around the United States. Treatments are applied according to our individualized strategies, ranging from observation with close monitoring to treatment with novel anti-myeloma drugs and/or to high-dose therapy with autologous stem cell transplantation.
Individualized strategies rely on full partnership and continual communication between the medical team and patient. Together, a comprehensive plan emerges that carefully balances medical, spiritual and social that gives the patient the benefit of the most effective therapy for his or her personal need as well as a positive quality of life.
Our team has more than 100 years of cumulative experience in the treatment of myeloma, leukemia, lymphoma and the bone marrow transplantation treatment process.
With diseases as complex as multiple myeloma, leukemia and lymphoma, this extensive experience offers a distinct advantage: subspecialized, expert care—delivered in full partnership with the patient and his or her loved ones.
Our staff focuses exclusively on the treatment of patients with cancers of the blood and bone marrow and is thoroughly knowledgeable in all treatment processes and the sequence of treatments. Because of this, the team is adept at anticipating potential complications and addressing patient/family needs quickly to ensure the best outcome for our patients.
UC Health's Bone Marrow Transplant Program as part of the UC Cancer Institute received accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) further demonstrating the excellence in care provided by experts within the institute. Programs with this distinction have met the most rigorous standards in all aspects of stem cell therapy.
FACT is an internationally recognized accrediting body for hospitals and medical institutions offering therapies that use adult stem cells, like bone marrow transplants and peripheral blood transplants for patients with blood cancers and diseases.
A nonprofit corporation co-founded in 1996 by the International Society for Cellular Therapy and the American Society of Blood and Marrow Transplantation, FACT establishes standards for high-quality medical and laboratory practice in cellular therapies. FACT standards are evidence-based requirements set by experts vested in the improvement and progress of cellular therapy.
24/7, 365-Day-a-Year Access
At the core of our program is a dedication to quality both in medical care and the overall patient experience. We have an aggressive commitment—backed by daily data collection and follow-up—to ensuring our patients thrive during cancer treatment and beyond.
Unique 24/7, 365 day-a-year onsite coverage by physicians who are experienced in myeloma, other hematological cancers and bone marrow transplantation is also provided to ensure immediate care for patients and avoid unnecessary emergency room visits.
Continuity of care using proven strategies when care is provided in Cincinnati as well as when patients return home to their local physicians.
The MyUCHealth patient portal is available online, offering 24/7 access to patient medical records and strategies to ensure a seamless and safe transition of care between our team and referring physicians, whether care in received in Cincinnati or at home for patients traveling from out of town.
This secure website allows patients to request an appointment, order prescription refills, complete pre-registration forms, pay bills, view medical records and more. Referring physicians can also gain access to a patient’s medical records via this system. Learn more about registration at uchealth.com.
- Subspecialty Partners in Care
Our relationship with strong clinical consultative services affiliated with the UC Cancer Institute—including radiology, pathology, immunology, orthopedics, neurology, neurosurgery, nephrology, endocrinology and cardiology—ensures that even the most complex clinical scenario can be managed by physicians with special interest and expertise in managing patients with hematologic cancers.
Working in close collaboration with the nationally recognized Hoxworth Blood Center and the UC College of Medicine Department of Pathology and Laboratory Medicine, our team has access to new techniques for blood and stem cell collection and safer transfusion methods as well as advanced scientific techniques for monitoring patient cancer markers and other molecular signatures pre-treatment to identify potential setbacks before they develop and address them effectively.